These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 22509073)
81. Molecular alterations contributing to pancreatic cancer chemoresistance. Rajabpour A; Rajaei F; Teimoori-Toolabi L Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383 [TBL] [Abstract][Full Text] [Related]
82. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer. Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943 [TBL] [Abstract][Full Text] [Related]
83. Pancreatic cancer. Kleeff J; Korc M; Apte M; La Vecchia C; Johnson CD; Biankin AV; Neale RE; Tempero M; Tuveson DA; Hruban RH; Neoptolemos JP Nat Rev Dis Primers; 2016 Apr; 2():16022. PubMed ID: 27158978 [TBL] [Abstract][Full Text] [Related]
84. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798 [TBL] [Abstract][Full Text] [Related]
85. Pancreatic cancer stem cell markers and exosomes - the incentive push. Heiler S; Wang Z; Zöller M World J Gastroenterol; 2016 Jul; 22(26):5971-6007. PubMed ID: 27468191 [TBL] [Abstract][Full Text] [Related]
86. Proteome-based biomarkers in pancreatic cancer. Sun C; Rosendahl AH; Ansari D; Andersson R World J Gastroenterol; 2011 Nov; 17(44):4845-52. PubMed ID: 22171124 [TBL] [Abstract][Full Text] [Related]
87. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Liu L; Salnikov AV; Bauer N; Aleksandrowicz E; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Schemmer P; Werner J; Herr I Int J Cancer; 2014 May; 134(10):2489-503. PubMed ID: 24615157 [TBL] [Abstract][Full Text] [Related]
88. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009 [TBL] [Abstract][Full Text] [Related]
89. Role of human nucleoside transporters in pancreatic cancer and chemoresistance. Carter CJ; Mekkawy AH; Morris DL World J Gastroenterol; 2021 Oct; 27(40):6844-6860. PubMed ID: 34790010 [TBL] [Abstract][Full Text] [Related]
90. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy. Mirza S; Jain N; Rawal R Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243 [TBL] [Abstract][Full Text] [Related]
91. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue. Gote V; Nookala AR; Bolla PK; Pal D Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129 [TBL] [Abstract][Full Text] [Related]
95. Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells. Timaner M; Letko-Khait N; Kotsofruk R; Benguigui M; Beyar-Katz O; Rachman-Tzemah C; Raviv Z; Bronshtein T; Machluf M; Shaked Y Cancer Res; 2018 Mar; 78(5):1253-1265. PubMed ID: 29301792 [TBL] [Abstract][Full Text] [Related]
96. Drug resistance in pancreatic cancer: New player caught in act. Capurso G; Sette C EBioMedicine; 2019 Feb; 40():39-40. PubMed ID: 30765320 [No Abstract] [Full Text] [Related]
97. Early detection of pancreatic cancer. Pereira SP; Oldfield L; Ney A; Hart PA; Keane MG; Pandol SJ; Li D; Greenhalf W; Jeon CY; Koay EJ; Almario CV; Halloran C; Lennon AM; Costello E Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):698-710. PubMed ID: 32135127 [TBL] [Abstract][Full Text] [Related]
98. Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy. Nwabo Kamdje AH; Dongmo Fogang HP; Mimche PN Front Mol Med; 2024; 4():1426454. PubMed ID: 39308891 [TBL] [Abstract][Full Text] [Related]
99. Safety and Effectiveness of Perioperative Hyperthermic Intraperitoneal Chemotherapy with Gemcitabine in Patients with Resected Pancreatic Ductal Adenocarcinoma: Clinical Trial EudraCT 2016-004298-41. Padilla-Valverde D; Bodoque-Villar R; García-Santos E; Sanchez S; Manzanares-Campillo C; Rodriguez M; González L; Ambrós A; Cano JM; Padilla-Marcote M; Redondo-Calvo J; Martin J; Serrano-Oviedo L Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730669 [TBL] [Abstract][Full Text] [Related]
100. Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41. Padilla-Valverde D; García-Santos E; Sanchez S; Manzanares C; Rodriguez M; González L; Ambrós A; Cano JM; Serrano L; Bodoque R; Vergara T; Martin J J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S80-S90. PubMed ID: 33968428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]